You make the assumption that competition comes from within. A common mistake. Pain management is not isolated to opioids. Time will change this myopic mentality soon.
One surprising note is that Nasrat stated SequestOx has 400M potential in sales. Caught that when reading prior call scripts. That is a small potential for a dent in IR, but not huge.